896-90-2

Upstream product

• 18066-68-7 ethyl 3,4-dimethoxyphenylacetate 
• 105-58-8 Diethyl carbonate 
• 95-92-1 oxalic acid diethyl ester 
• 623-49-4 ethyl cyanoformate 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 

Downstream Products

• 121324-66-1 2-(3,4-Dimethoxy-phenyl)-N,N'-dipropyl-malonamide 
• 121324-68-3 N,N'-Dicyclohexyl-2-(3,4-dimethoxy-phenyl)-malonamide 
• 121324-71-8 2-(3,4-Dimethoxy-phenyl)-N,N'-bis-[2-(3,4-dimethoxy-phenyl)-ethyl]-malonamide 
• 121324-65-0 N,N-Diethyl-2-(3,4-dimethoxy-phenyl)malonamide 
• 121324-70-7 2-(3,4-Dimethoxy-phenyl)-N,N'-diphenethyl-malonamide 
• 121324-67-2 N,N'-Dibutyl-2-(3,4-dimethoxy-phenyl)-malonamide 
• 118657-11-7 diethyl α-<1-(3,4-dimethoxyphenyl)>-α-acetoxymalonate 
• 717-51-1 2-(3,4-dimethoxy-phenyl)-1,3-propane-diol 
• 926008-52-8 5-(3,4-dimethoxyphenyl)pyrimidine-4,6-diol 
• 146533-38-2 4,6-dichloro-5-(3,4-dimethoxyphenyl)pyrimidine 
• 926008-72-2 {4-[6-chloro-5-(3,4-dimethoxyphenyl)pyrimidin-4-ylethynyl]phenyl}dimethylamine 
• 121324-72-9 2-(3,4-Dimethoxy-phenyl)-N,N'-diethyl-propane-1,3-diamine 
• 121324-73-0 2-(3,4-Dimethoxy-phenyl)-N,N'-dipropyl-propane-1,3-diamine 
• 121324-74-1 N,N'-Di-n-butyl-2-(3,4-dimethoxy-phenyl)-1,3-propane-diamine 

Relevant academic research and scientific papers

Enzymatic desymmetrization of prochiral 2-substituted-1,3-diamines: Preparation of valuable nitrogenated compounds

A wide range of prochiral 1, 3-diamines were first efficiently synthesized and subsequently desymmetrized by using lipase from Pseudomonas cepacia as catalyst and diallyl carbonate as alkoxycarbonylating agent. In all cases, the amino carbamates of R-configuration were recovered. Final selective cleavage of the N-allyloxycarbonyl moiety was carried out under mild reaction conditions, which demonstrates the high versatility and potential of this chemoenzymatic route as a source of intermediates in the synthesis of related optically active nitrogenated derivatives.

4-Amino-5-aryl-6-arylethynylpyrimidines: Structure-activity relationships of non-nucleoside adenosine kinase inhibitors

A series of non-nucleoside adenosine kinase (AK) inhibitors is reported. These inhibitors originated from the modification of 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine (ABT-702). The identification of a linker that would approximate the spatial arrangement found between the pyrimidine ring and the aryl group at C(7) in ABT-702 was a key element in this modification. A search of potential linkers led to the discovery of an acetylene moiety as a suitable scaffold. It was hypothesized that the aryl acetylenes, ABT-702, and adenosine bound to the active site of AK (closed form) in a similar manner with respect to the orientation of the heterocyclic base. Although potent acetylene analogs were discovered based on this assumption, an X-ray crystal structure of 5-(4-dimethylaminophenyl)-6-(6-morpholin-4-ylpyridin-3-ylethynyl)pyrimidin-4-ylamine (16a) revealed a binding orientation contrary to adenosine. In addition, this compound bound tightly to a unique open conformation of AK. The structure-activity relationships and unique ligand orientation and protein conformation are discussed.